News › Industry News, News

Novo Nordisk Reveals Plan to Build Mammoth $4.1B Plant in North Carolina to Help Produce Ozempic, Wegovy

June 28, 2024
Bar graph showing growth

GLP-1 heavyweights Eli Lilly and Novo Nordisk are trading haymakers as they scale up production to meet the overwhelming demand for their revolutionary obesity drugs.

A month after Lilly revealed a $5.3 billion investment to increase its manufacturing capacity, Novo has answered.

On Monday, the Danish drugmaker said it will spend $4.1 billion to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina. At 1.4 million square feet, the site will match the combined floor space of Novo’s three current manufacturing sites in the state, the company said.

Read more at Fierce Pharma >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • 10 Marketing Truths Every Aesthetic Practice Needs to Hear Right Now
    • AI, FDA, PDGF: The Talk of MSS
    • Radiologists Warn that Décolletage Filler May Interfere with Breast Cancer Screening
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical